Revolutionising healthcare with peptide-based therapies in specialist therapeutic areas

ImmuPharma PLC is an AIM listed (LSE:IMM) evolving speciality Bio-pharma company that discovers and develops peptide-based therapeutics. The Company is headquartered in London with its R&D team, ImmuPharma Biotech, based in France.

The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 is a first-in class immune “restorer” for the treatment of autoimmune diseases and is in Phase 3 for SLE (Lupuzor™ is the disease trademark).

Preclinical analysis suggests therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action, based on the P140 platform technology.

ImmuPharma and Avion Pharmaceuticals have an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 study for Lupuzor™ and commercialise in the US.

4 core lead assets, 2 at late clinical stage

Lupuzor™

Autoimmunity

Lupus

Status
Phase 3 study (pivotal)

Study start
2023/24

P140

Inflammation

CIDP

Status
Phase 2/3 adapative (pivotal)

Study start
2023/24

BioAMB

Anti-infection

Severe Fungal infection

Status
Late pre-clinical

Partnering
2023/24

BioCIN

Anti-infection

Severe Bacterial infection

Status
Late pre-clinical

Partnering
2023/24

Visit our pipeline page

Why Invest in ImmuPharma?

A rich portfolio with 2 highly attractive late-stage clinical indications – SLE & CIDP
Near-term business development opportunities across all programs
Innovative P140 Bio-drug platform has the potential in several autoimmune diseases and life cycle management through it’s second generation P140